This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gladstone, D E Articles by Brodsky, I Search for Related Content PubMed PubMed Citation Articles by Gladstone, D E Articles by Brodsky, I Social Bookmarking                         What's this?

High-dose cyclophosphamide for severe systemic lupus erythematosus

Drexel University, College of Medicine, Department of Medicine, Philadelphia, PA, USA: 245 North 15th Street, MS 412, Philadelphia, PA 19102, USA; deg25{at}drexel.edu

A A Prestrud

A Pradhan

M J Styler

D L Topolsky

P A Crilley

S Hoch

A Huppert

I Brodsky

Drexel University, College of Medicine, Department of Medicine, Philadelphia, PA, USA

Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 mg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 £ 10 ⁹=l for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dosecyclophosphamide,SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measuredby SLAM-2 and SLEDAI was 15.5 (range 11–19) and 23.25 (range 20–26), respectively. At a median of 22 (range 12–39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.

Key Words: cyclophosphamide • high-dose therapy • SLAM • SLE • SLEDAI

Lupus, Vol. 11, No. 7, 405-410 (2002)
DOI: 10.1191/0961203302lu229oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]

				D. E. Gladstone, K. W. Zamkoff, L. Krupp, R. Peyster, P. Sibony, C. Christodoulou, E. Locher, and P. K. Coyle High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis Arch Neurol, October 1, 2006; 63(10): 1388 - 1393. [Abstract] [Full Text] [PDF]

				L N Moorthy, M J Harrison, M Peterson, K B Onel, and T J. Lehman Relationship of quality of life and physical function measures with disease activity in children with systemic lupus erythematosus Lupus, April 1, 2005; 14(4): 280 - 287. [Abstract] [PDF]

				M Petri Cyclophosphamide: new approaches for systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 366 - 371. [Abstract] [PDF]

				M. Sonmezer and K. Oktay Fertility preservation in female patients Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266. [Abstract] [Full Text] [PDF]